Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Phillip Capital

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Mid-range Performer

1636.7000 -2.50 (-0.15%)

NSE Jun 20, 2025 15:31 PM

36.47% Gain from 52W Low

Volume: 1.2M

Glenmark Pharmaceuticals Ltd.

16 May 2016

1636.70

-0.15%

Glenmark Q4FY16 Update 16May2016

Buy: Glenmark Pharmaceuticals Ltd.

Target

Phillip Capital

ROW (+36%) and LatAm (+34%) sales. US sales of US$ 97mn were inline with our estimates.CoreoperatingmarginadjustingforforexlossofRs840mnandonetime SitagliptinrelatedlitigationcostofRs650mn)compressedby~260bpsyoyto19.8%...

Glenmark Pharmaceuticals Ltd. has gained 31.86% in the last 1 Year